<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. _______________)*
SCHEIN PHARMACEUTICAL, INC.
---------------------------
(NAME OF ISSUER)
COMMON STOCK, PAR VALUE $0.01 PER SHARE
---------------------------------------
(Title of Class of Securities)
806416103
---------
(CUSIP Number)
April 8, 1998
-------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|__| Rule 13d-1(b)
|__| Rule 13d-1(c)
| x | Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 Pages
<PAGE> 2
- ------------------------
CUSIP No. 806416103 13G
- ------------------------
- ---------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Bayer Corporation
- ---------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)
(b) X
- ---------- --------------------------------------------------------------------
3 SEC USE ONLY
- ---------- --------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Indiana
- ---------- --------------------------------------------------------------------
5 SOLE VOTING POWER
8,141,910
NUMBER OF
SHARES ----------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY EACH
REPORTING 0
PERSON WITH
----------------------------------------------------
7 SOLE DISPOSITIVE POWER
8,141,910
----------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
- ---------- --------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,141,910
- ---------- --------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
- ---------- --------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
25.1%[Calculated based on shares outstanding at September 26, 1998 of
32,429,888]
- ---------- --------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
CO
- ---------- --------------------------------------------------------------------
Page 2 of 5 Pages
<PAGE> 3
SCHEDULE 13G
ITEM 1(a). NAME OF ISSUER: Schein Pharmaceutical, Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
100 Campus Drive
Florham Park, NJ 07932
ITEM 2.
ITEM 2(a) Name of Person Filing:
Bayer Corporation
ITEM 2(b) Address of Principal Business Office or, if None, Residence:
100 Bayer Road, Pittsburgh, PA 15205
ITEM 2(c) Citizenship:
Indiana
ITEM 2(d) Title of Class of Securities:
Common Stock, $.01 par value
ITEM 2(e) CUSIP Number:
806416103
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13D-1(b), OR
13D-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a) |__| Broker or dealer registered under Section 15 of
the Exchange Act.
(b) |__| Bank as defined in Section 3(a)(6) of the
Exchange Act.
(c) |__| Insurance company registered under Section 8 of
the Investment Company Act.
(d) |__| Investment company registered under Section 8 of
the Investment Company Act.
(e) |__| An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E).
(f) |__| An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F).
ITEM 4. OWNERSHIP
Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer
identified in Item 1.
(a) Amount beneficially owned: 8,141,910 shares.
(b) Percent of class: 25.1%
Page 3 of 5 Pages
<PAGE> 4
SCHEDULE 13G
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
8,141,910 shares.
(ii) Shared power to vote or to direct the vote: 0
shares.
(iii) Sole power to dispose or to direct the
disposition of: 8,141,910 shares.
(iv) Shared power to dispose or to direct the
disposition of: 0 shares.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [ ].
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON.
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION
Not applicable.
Page 4 of 5 Pages
<PAGE> 5
SCHEDULE 13G
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 12, 1999
-------------------------------------
Date
/s/ Jon R. Wyne
-------------------------------------
Signature
Senior Vice President and Treasurer
-------------------------------------
Name/Title
Page 5 of 5 Pages
